2022
Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy
Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, Wong RJ, Dunn L, Pfister DG, Sherman EJ, Lee NY. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncology 2022, 8: 364-372. PMID: 35050342, PMCID: PMC8778604, DOI: 10.1001/jamaoncol.2021.6416.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalMetastasis-free survivalOropharyngeal carcinomaConcurrent chemoradiotherapyDe-escalation strategiesRadiotherapy doseTotal doseSubclinical regionsLocoregional controlGross diseaseCohort studyOverall survivalClinical outcomesHuman Papillomavirus–Associated Oropharyngeal CarcinomaHigh-dose cisplatin therapyHPV-positive oropharyngeal carcinomaTarget volumeBilateral level IBGy of radiotherapyPrimary concurrent chemoradiotherapyRetrospective cohort studyFavorable clinical outcomeAmerican Joint CommitteeLong-term follow
2020
Radical Reduction of Radiation Therapy Dose Prescription for Elective Treatment Areas in Human Papillomavirus (HPV) - Associated Oropharyngeal Carcinoma (OPC)
Tsai C, McBride S, Riaz N, Kang J, Yu Y, Chen L, Gelblum D, Wong R, Boyle J, Dunn L, Sherman E, Pfister D, Lee N. Radical Reduction of Radiation Therapy Dose Prescription for Elective Treatment Areas in Human Papillomavirus (HPV) - Associated Oropharyngeal Carcinoma (OPC). International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1143-1144. DOI: 10.1016/j.ijrobp.2019.11.209.Peer-Reviewed Original ResearchOropharyngeal carcinomaHuman Papillomavirus–Associated Oropharyngeal CarcinomaDose prescriptionTreatment areaCarcinoma